Patents by Inventor Jonathan Bortz
Jonathan Bortz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220257805Abstract: The present disclosure provides pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to CD206. In an aspect, the present disclosure encompasses a pharmaceutical formulation for administration. The pharmaceutical formulation comprises a recombinantly produced intrinsic factor (IF), wherein the IF has a glycosylation pattern that enables binding to CD206.Type: ApplicationFiled: May 20, 2020Publication date: August 18, 2022Inventors: Jonathan Bortz, Robert Doyle, Jayme Workinger
-
Publication number: 20220160830Abstract: The present disclosure provides a single dose form composition to optimize the relationship between the ‘Tolate-Cobalamin’ and ‘Choline-Betaine’ pathways. Single dose form compositions disclosed herein ensure an adequate intake of the rate limiting compounds that have been demonstrated to reduce the efficiency of this vital metabolic axis, and methods of use thereof.Type: ApplicationFiled: February 11, 2022Publication date: May 26, 2022Inventor: Jonathan Bortz
-
Patent number: 11278591Abstract: The present disclosure provides a single dose form composition to optimize the relationship between the ‘Folate-Cobalamin’ and ‘Choline-Betaine’ pathways. Single dose form compositions disclosed herein ensure an adequate intake of the rate limiting compounds that have been demonstrated to reduce the efficiency of this vital metabolic axis, and methods of use thereof.Type: GrantFiled: March 20, 2017Date of Patent: March 22, 2022Assignee: Balchem CorporationInventor: Jonathan Bortz
-
Publication number: 20190125828Abstract: The present disclosure provides a single dose form composition to optimize the relationship between the ‘Folate-Cobalamin’ and ‘Choline-Betaine’ pathways. Single dose form compositions disclosed herein ensure an adequate intake of the rate limiting compounds that have been demonstrated to reduce the efficiency of this vital metabolic axis, and methods of use thereof.Type: ApplicationFiled: March 20, 2017Publication date: May 2, 2019Inventor: Jonathan Bortz
-
Publication number: 20170281554Abstract: A preparation for releasing an active substance, such as iron, in the upper intestine includes an oral dosage form having an external coating, a coating matrix enveloping the oral dosage form, and the active substance embedded in the coating matrix. The active substance disintegrates from the coating matrix within at least one of the stomach, duodenum, upper jejunum, or any combination thereof.Type: ApplicationFiled: March 29, 2017Publication date: October 5, 2017Inventor: Jonathan Bortz
-
Publication number: 20130172279Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.Type: ApplicationFiled: July 25, 2012Publication date: July 4, 2013Applicant: DRUGTECH CORPORATIONInventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
-
Patent number: 8425956Abstract: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.Type: GrantFiled: July 25, 2011Date of Patent: April 23, 2013Assignee: Albion International, Inc.Inventors: R. Charles Thompson, Clayton Ericson, Stephen Ashmead, Jonathan Bortz
-
Publication number: 20120022162Abstract: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.Type: ApplicationFiled: July 25, 2011Publication date: January 26, 2012Applicant: Albion International Inc.Inventors: R. Charles Thompson, Clayton Ericson, Stephen Ashmead, Jonathan Bortz
-
Publication number: 20110251141Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.Type: ApplicationFiled: June 20, 2011Publication date: October 13, 2011Applicant: DRUGTECH CORPORATIONInventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
-
Patent number: 8007846Abstract: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.Type: GrantFiled: January 16, 2007Date of Patent: August 30, 2011Assignee: Albion International, Inc.Inventors: R. Charles Thompson, Clayton Ericson, Stephen Ashmead, Jonathan Bortz
-
Publication number: 20080139655Abstract: A pharmaceutical composition comprising levodopa is provided that, when administered in a unit dosage amount of levodopa of about 100 to about 500 mg at a dosage interval of about 6 to about 24 hours, exhibits a sufficiently long release period and a sufficiently long residence time in the upper gastrointestinal tract to provide a trough concentration of levodopa in plasma of the subject that is not lower than a minimum threshold concentration below which adverse motor effects are observed in the subject. A method for treating Parkinson's disease in a subject is also provided, comprising orally administering such a composition to the subject in a unit dosage amount of levodopa of about 50 to about 1000 mg at a dosage interval of about 3 to about 24 hours.Type: ApplicationFiled: September 5, 2007Publication date: June 12, 2008Applicant: DrugTech CorporationInventors: Jonathan Bortz, Michael Grimshaw, David F. Erkoboni, Michael F. Dickus
-
Publication number: 20080085877Abstract: A method for preventing or treating a catamenial migrainous disorder in a female subject comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition that is bioadhesive thereto and comprises at least one estrogenic compound in an amount of about 50 ?g to about 1000 ?g estradiol equivalent per unit dose of the composition. A related method comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition comprising at least one estrogenic compound, wherein upon administration of the composition to the vulvovaginal surface, a decline in serum estradiol concentration during a luteal phase of a menstrual cycle is moderated.Type: ApplicationFiled: August 10, 2006Publication date: April 10, 2008Applicant: DrugTech CorporationInventor: Jonathan Bortz
-
Publication number: 20080003262Abstract: A method for treating non-infectious inflammatory vulvovaginitis comprises administering to a vulvovaginal surface a pharmaceutical composition that comprises clindamycin in an amount of about 125 mg to about 400 mg per unit dose of the composition; wherein the composition is bioadhesive to the vulvovaginal surface, and upon application of the composition to the vulvovaginal surface the clindamycin is released over a period of about 3 hours to about 14 days. A related method comprises administering to a vulvovaginal surface a pharmaceutical composition comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, wherein the composition has at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. A pharmaceutical composition comprises (a) clindamycin or a pharmaceutically acceptable salt or ester thereof in a clindamycin equivalent amount of about 2.Type: ApplicationFiled: June 28, 2007Publication date: January 3, 2008Applicant: DrugTech CorporationInventors: R. Saul Levinson, Robert C. Cuca, Jonathan Bortz
-
Publication number: 20070224226Abstract: A pharmaceutical composition comprises (a) metronidazole in an antibacterially effective amount; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.Type: ApplicationFiled: December 28, 2006Publication date: September 27, 2007Applicant: DrugTech CorporationInventors: R. Levinson, Jonathan Bortz, Mitchell Kirschner, Robert Cuca
-
Publication number: 20070172551Abstract: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in order to further improve solubility, absorption, and/or bioavailability. Compositions including one or more mixed amino acid/mineral compounds can be included in therapeutic regimens for indications in which the mineral may treat and/or prevent a condition or symptom.Type: ApplicationFiled: January 16, 2007Publication date: July 26, 2007Applicant: ALBION ADVANCED NUTRITIONInventors: R. Thompson, Clayton Ericson, Stephen Ashmead, Jonathan Bortz
-
Publication number: 20070154516Abstract: A pharmaceutical composition comprises a first active (e.g., antibacterial) agent and a second (e.g., antifungal) active agent, and comprises a component that is adapted for bioadhesion to a vulvovaginal surface. The composition provides differential release of the active agents at such a surface, wherein the second active agent exhibits a release profile that is substantially delayed, extended and/or inverted relative to the release profile of the first active agent.Type: ApplicationFiled: December 28, 2006Publication date: July 5, 2007Applicant: DrugTech CorporationInventors: Jonathan Bortz, R. Levinson
-
Publication number: 20070154498Abstract: A method for preventing stenosis and thrombosis of an AV graft is disclosed. An essential fatty acid emulsion is administered to the patient through the AV graft, preferably during dialysis, whereby the anti-inflammatory properties of the essential fatty acid emulsion prevent complications typical of AV grafts.Type: ApplicationFiled: December 6, 2006Publication date: July 5, 2007Inventors: Jonathan Bortz, R. Levinson
-
Publication number: 20070110805Abstract: This invention is directed generally to modified-release pharmaceutical compositions, and, more particularly, to modified-release anesthetic- or analgesic-comprising pharmaceutical compositions that are bioadherent to a vaginal cavity surface, vulva surface, or skin. This invention also is directed generally to methods for preparing such compositions, methods of treatment using such compositions, uses of such compositions to prepare medicaments, and kits comprising such compositions.Type: ApplicationFiled: May 8, 2006Publication date: May 17, 2007Inventors: R. Levinson, Jonathan Bortz, Elio Mariani, Daniel Thompson
-
Publication number: 20070036848Abstract: A pharmaceutical composition comprises at least one estrogenic compound, the composition being adapted for application in a unit dose amount to a vulvovaginal surface and having at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface, wherein the at least one estrogenic compound is present in an amount of about 5 to about 1000 ?g estradiol equivalent per unit dose of the composition, and upon application of the composition to the vulvovaginal surface the at least one estrogenic compound is released over a period of about 3 hours to about 30 days. The composition is useful for vulvovaginal administration to treat atrophic vaginitis or a disorder associated therewith, for example in a menopausal or postmenopausal woman.Type: ApplicationFiled: August 10, 2006Publication date: February 15, 2007Applicant: DrugTech CorporationInventors: Jonathan Bortz, Thomas Riley
-
Publication number: 20060140990Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.Type: ApplicationFiled: January 5, 2006Publication date: June 29, 2006Applicant: DrugTech CorporationInventors: Jonathan Bortz, R. Levinson, Mitchell Kirschner, Robert Cuca